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List of Abbreviations 
 
NSAID Nonsteroidal Anti-inflammatory drug 
OA  Osteoarthritis 
WOMAC Western Ontario and McMaster Universities Osteoarthritis Index 
VAS  Visual analogue scale 
LPFI  Lequesne Pain and Function Index 
KOA  Knee osteoarthritis 
ROS  Reactive oxygen species 
ADL  Activity of daily living 
BMI  Body mass index 
	   	  
	  
Objective: To determine if curcumin supplementation compared to nonsteroidal anti-
inflammatory drugs (NSAIDs), placebo, and rescue medications is an effective treatment of 
arthritic symptoms in males and females between the ages of 50 and 80 with a diagnosis of 
osteoarthritis. 
Design: Systematic Literature Review  
Methods: Searches were done in PubMed, Google Scholar, and Scopus utilizing the terms 
“turmeric”, “curcumin”, “osteoarthritis”, “NSAIDs”, “ibuprofen”, and “placebo.”  The following 
limits were applied: excluded if compared greater than two remedies for treatment of 
osteoarthritis or if turmeric was used as an “add-on” for treatment.  Articles were included if they 
only dealt with human subjects, were published in 2014 or later, and were full-text. 
Results: A randomized control trial by Kuptniratsaikul, V. et al concluded that curcumin was as 
efficacious as ibuprofen in reducing pain and improving function associated with Osteoarthritis 
(OA) with the benefit that curcumin resulted in less gastrointestinal complaints.   Srivastave, S. et 
al concluded that curcumin can be used with diclofenac to provide relief in patients with knee 
OA. The results demonstrated that patients in the curcumin and diclofenac group had 
improvement in all three measures of the Western Ontario and McMaster Universities 
Osteoarthritis Index (WOMAC) score when compared to patients in the placebo group. Panahi 
Y. et al study showed a statistical significant improvement in measures of the WOMAC score in 
the curcumin group while the placebo group showed no change in WOMAC parameters. The 
curcumin group also had significant reduction in Visual Analogue Scale (VAS) and Lequesne 
Pain and Function Index (LPFI) scores compared to placebo. 
Conclusion: Curcumin may provide relief of osteoarthritic symptoms as demonstrated by 
subjective measures of pain and objective measures of inflammation. Additionally, curcumin has 
a strong safety profile, a low potential for toxicity, and few adverse side effects those of which 
include gastrointestinal symptoms such as diarrhea and flatulence. Further research is needed to 
investigate the relationship between curcumin and the impact on osteoarthritic symptoms 
independent of NSAIDs. Additionally, population based studies are needed to see if the results of 




  Osteoarthritis (OA) is a degenerative joint disease characterized by joint pain, stiffness, 
and restricted movement and is a leading cause of chronic disability in adults. Also called 
degenerative joint disease, OA is characterized by sclerosis, osteophytosis, and joint space 
narrowing. Weight bearing joints are frequently impacted and lead to increased disability and 
impaired functioning of daily living activities (6).  Commonly affected joints include the hands, 
hips, knees and shoulders. A study conducted in 2005 estimated that over 27 million Americans 
live with OA representing nearly 10% of the US population (1). Two major risk factors for the 
development of OA include age and obesity. According to one study, the lifetime risk of 
developing symptomatic knee arthritis was one in two people will develop symptomatic knee 
arthritis by the age of 85 and two thirds of obese individuals will also develop OA (1). Despite 
the prevalence and the impact on daily living, there are limited treatment options for OA. 
The development of osteoarthritis is multifactorial, and the pathogenesis is complex. OA 
is characterized by inflammation at the molecular level rather than the cellular level. The 
development of OA involves the production of pro-inflammatory mediators and alterations in the 
synovium and soft tissue of joints. When individuals are affected with OA, the body produces 
pro-inflammatory mediators, including cytokines that stimulate the production of proteolytic 
enzymes leading to breakdown of the articular cartilage.  The synovium is also affected which 
contributes to the development of pain and swelling.  Over time, with increased breakdown of 
the cartilage, the pain and inflammation worsens.  Due to this effect, patients may experience 
pain that worsens with activity and improves with rest.  
 Current treatment modalities for osteoarthritis are centered on symptom management 
which encompass lifestyle changes such as weight loss, pharmacological treatment, and surgical 
intervention.  Treatment for OA targets relief of symptoms with the use of nonsteroidal anti-
inflammatory agents (NSAIDs), opioid analgesics, and intraarticular injections.  Although 
research has investigated the development of disease modifying drugs for the treatment of OA, 
currently there is no FDA approved pharmacological treatment designed to change the 
progression of the disease (3).  
While NSAIDs remain the agent of choice for pain management in OA, long term use of 
NSAIDs is associated with several adverse side effects, including gastrointestinal, renal, and 
cardiovascular symptoms. This has led to an increased interest in herbal supplements for the 
treatment of OA including curcumin.  Curcumin is a yellow substance that comes from the 
rhizomes of Cercuma Longa, otherwise known as turmeric (4). Although curcumin was 
discovered in 1748, its first documented use in humans was not until 1937 when a paper was 
published demonstrating the effect of curcumin in treating cholecystitis. Since then, further 
studies have demonstrated that curcumin is safe, tolerable, and nontoxic in humans (5). Later 
research has found curcumin to have anti-inflammatory and antioxidant properties, and it is 
capable of inhibiting some of the pro-inflammatory mediators frequently seen in the 
development of OA.   
To date there is limited research on the effects of curcumin on symptom relief for 
osteoarthritis; however, the research may suggest curcumin to have the same effect as NSAIDs 
with the addition of limited gastrointestinal side effects. Therefore, the present study sought to 
evaluate the effectiveness of curcumin in relieving symptoms of OA in males and females 





An initial search of PubMed, Google Scholar, and Scopus was performed in September 
2017 using the search terms “turmeric”, “curcumin”, “osteoarthritis”, “NSAIDs”, “ibuprofen”, 
and “placebo” yielding 32 results (See Figure 1).  Duplicate articles were removed, and the 
articles were further searched and only included if they were randomized control trials published 
in 2013 or later with full text articles available. This narrowed the results to 12 articles. The 12 
full-text articles were assessed for eligibility and were excluded if they compared greater than 
two remedies for treatment of osteoarthritis or if curcumin was used as an “add-on” for 
treatment, yielding eight articles. Individual articles were reviewed, and three randomized 
control trials were chosen as they were the only three comparing curcumin to a different 





























Figure 1. PRISMA flow diagram summarizing the article search process. 
Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: 
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Efficacy and safety of Curcuma domestica extracts compared with ibuprofen in patients with 





This randomized control trial’s goal was to determine the efficacy and safety of curcumin 
in pain reduction and functional improvement compared with ibuprofen in patients with 
osteoarthritis. 
 
Study Design:  
 
Participants were recruited from eight tertiary hospitals in Thailand from July 2010 to 
March 2012.  Eligibility requirements included being a primary knee osteoarthritis patient 
according to the American Rheumatism Association criteria and having a numerical score of 
knee pain of ≥ 5 out of 10 and age ≥ 50 years.  Patients were excluded if they had abnormal liver 
function or renal function, history of peptic ulcer, allergy to curcumin or ibuprofen, or were 
unable to walk.  All inclusion and exclusion criteria is summarized in Table 1. All participants 
received a knee x-ray to indicate severity of OA according to the Kellgren-Lawrence criteria, a 
method of classifying the severity of knee osteoarthritis using a 0-4 scale depicted in Table 2 (6).  
 
Table 1. Patient Inclusion and Exclusion Criteria; Kuptniratsaikul, V. et al 2014 
 
Inclusion Criteria 
Primary knee osteoarthritis patients according to American Rheumatism Association criteria 
Numerical score of knee pain at least 5 out of 10 
Age at least 50 years old  
Exclusion Criteria 
Abnormal liver or renal function 
History of peptic ulcers 
Allergy to curcumin or ibuprofen 





Table 2. Kellgren/Lawrence Osteoarthritis grading 
Grade  Classification 
Grade 0 no radiographic features of OA are present 
Grade 1  doubtful joint space narrowing (JSN) and possible osteophytic lipping  
Grade 2  definite osteophytes and possible JSN on anteroposterior weight-bearing radiograph  
Grade 3  multiple osteophytes, definite JSN, sclerosis, possible bony deformity 
Grade 4  large osteophytes, marked JSN, severe sclerosis and definite bony deformity 
 
 
Subjects were randomized by computer to receive either 1,200 mg/day of ibuprofen or 
1,500 mg/day of curcumin. Patients took two capsules after meals three times a day for four 
weeks and were not allowed to take other medications during the study.  Outcomes were 
measured at week 2 and week 4 by the same assessor.  Outcomes measured included the Western 
Ontaria and McMaster Universities Osteoarthritis Index (WOMAC) and a 6-minute walk 
distance.  WOMAC is a widely used standardized questionnaire used to evaluate the condition of 
patients with osteoarthritis of the knee and hip. WOMAC is broken down into 3 subscales; pain, 
stiffness, and function, each on a scale from 0-10, the higher the score the worse off (7).  
Adverse events were also compared between the two groups. Further, compliance of treatment 
was assessed using pill count at each visit. At the end of the study, patient’s global assessment 
and satisfaction was evaluated.   
The final sample size included 331 patients; 160 ibuprofen and 171 curcumin 
participants. The mean score of WOMAC and the 6-minute walk distance at week 4 were 
compared between groups using analysis of covariance and the unpaired t-test.  The adverse 
events and satisfaction levels were analyzed using chi-square and the compliance of the drug 




The primary outcome focused on for this study was the WOMAC scores and the 6-
minute walk test.  Eligible treatment group distribution is shown in table 3.  The baseline 
characteristics of participants were no different between the two randomized groups. 
Table 3. Distribution of patients randomized to the treatment groups; Kuptniratsaikul, V. et al 
2014 
Patients Curcumin Ibuprofen 
Initial 185 182 
Withdrawal Week 2 3 8 
Withdrawal Week 4 11 14 
Completed study 171 160 
 
 Group comparison of the WOMAC scores showed statistically significant improvement 
from baseline, however, the between-group comparison showed no difference in WOMAC 
scores showing that the curcumin group was non-inferior to the ibuprofen group.  Concerning the 
effectiveness of curcumin, the primary outcomes of WOMAC and the 6-minute walk were 
compared at week 4. The total WOMAC score for the curcumin was 3.36 while the ibuprofen 
group total was 3.23.  Broken down by section WOMAC pain subscale was a 3.25 for curcumin 
versus 3.17 for ibuprofen.  The WOMAC stiffness subscale was 3.28 for curcumin and 3.16 for 
ibuprofen, and WOMAC function was 3.41 for curcumin compared to 3.26 ibuprofen.  The 6-
minute walk in meters was 345.43 for the curcumin group compared to 347.99 for the ibuprofen 
group. In summary, both the ibuprofen and the curcumin group showed improvement from 
baseline. The WOMAC total score, pain, and functional ratings were equivocal between the two 
groups. However, the curcumin group had greater reductions in the WOMAC stiffness scale 
compared to the ibuprofen group which trended towards statistical significance (P value= 0.060). 
Additionally, the number of patients that reported abdominal discomfort was significantly higher 
in the ibuprofen group compared to the curcumin group (P value= 0.046)  (see Table 4). 
 
Table 4. Mean and SD for WOMAC and 6-minute walk distance at week 4 in ibuprofen and 
curcumin groups; Kuptniratsaikul, V. et al 2014 
 
Mean score at week 4 Ibuprofen (n = 160) Curcumin (n = 171) P-value 
WOMAC score total 3.23 ±  1.97 3.36 ±  2.04 0.010 
WOMAC pain 
subscale 
3.17 ±  1.98 3.25 ±  2.11 0.018 
WOMAC stiffness 
subscale 
3.16 ±  2.36 3.28 ±  2.38 0.060 
WOMAC function 
subscale 
3.26 ±  2.05 3.41 ±  2.09 0.010 
6-minute walk 
(meters) 
347.99 ±  86.60 345.43 ±  91.66 0.320 
 
 Secondary outcomes showed that overall there was no difference between adverse effects 
between the groups, 35.7% in ibuprofen and 29.7% in the curcumin group, P = 0.222.  Common 
adverse effects included dyspepsia, abdominal pain/distension, nausea, loose stool, and pitting 
edema.  The rate of abdominal pain/distension was significantly lower in the curcumin group at 
10.8% than in the ibuprofen group at 18.1%.  Rates of dyspepsia, nausea, and pitting edema were 
higher in the ibuprofen group compared to the curcumin group.  Only the symptom of loose stool 












Table 5. Adverse events occurring during study compared between two groups; Kuptniratsaikul, 
V. et al 2014 
 
Adverse events Ibuprofen (n = 182) Curcumin (n = 185) P-value 
Percentage of patients 
with adverse event 
35.7% 29.7% 0.222 
Abdominal 
pain/distension 
18.1% 10.8% 0.046* 
Dyspepsia 15.9% 11.4% 0.201 
Nausea 8.2% 4.9% 0.191 
Loose stool 8.8% 11.9% 0.330 
Melena 1.1% 0% 0.245 
Pitting edema 7.1% 3.8% 0.156 
 
 
In addition, there was no statistical difference in drug compliance between the groups, 
93.8% compliance in the ibuprofen group and 92.6% in the curcumin group; p-value 2.202.  The 
patient’s global assessment and satisfaction at week 4 also showed no difference between groups, 
however, 96% and 97% of subjects in the ibuprofen and curcumin groups respectively, were 
satisfied with the treatment.  Further 63.8% and 64.3% respectively rated themselves as 
improved (Table 6). 
 
 
Table 6. Percentage of patient’s global assessment and satisfaction at week 4; Kuptniratsaikul, 
V. et al 2014 
 
Variables  Ibuprofen (n=160) Curcumin (n=171) P-value 
Global assessment   0.665 
     Improved 63.8% 64.3% 
     Indifferent 32.5% 33.9% 
     Deteriorated 3.7% 1.8% 
Satisfaction index   0.707 
     Satisfied 95.6% 97.1% 
     Indifferent 4.4% 2.3% 
     Unsatisfied 0.0% 0.6% 
 
 Based on all of the results stated above, Kuptniratsaikul concluded that curcumin is as 
effective as ibuprofen for the treatment of knee osteoarthritis.  The side effect profile was similar 





 A strength of this article was the fact that it is a double-blind randomized controlled trial.  
Further, strict inclusion and exclusion criteria were used to avoid confounding variables.  
Examples of this include defining osteoarthritis according to the American Rheumatism 
Association criteria and not including patients with co-morbid conditions such as renal and liver 
disease. Both medications were manufactured by the Department of Pharmacy, Siriraj Hospital, 
Bangkok, Thailand, in the form of a capsule, to make them identical in appearance. The 
treatment codes were further kept by a pharmacist who was not involved in the study process.  
An additional strength of this study was the large sample size, with a total of 331 participants 
completing the study.  Most other articles comparing curcumin had sample sizes much smaller, 
typically with twenty to fifty patients total.   
 One drawback to this study was the use of multiple subjective results.  These included the 
Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), adverse events 
reported, as well as global assessment and overall satisfaction.  The only objective data measured 
in this study was the 6-minute walk test.  Another limitation to the study was the short duration 
at only 4 weeks.  The short duration of the study may have skewed the results, thus resulting in 
no statistical significance overall.  
 Another consideration when evaluating this article is when it comes to comparing the 
patient population in Thailand to the population in the United States.  Although the study was 
completed in Thailand, the results can still be applied to a United States population.  This is 
because osteoarthritis is a degenerative joint disease which can affect anyone regardless of where 
they live.  There are different degrees of severity of OA, however, this is true regardless of what 
country a person lives in.  Further, the strict inclusion and exclusion criteria of this study, which 
were according to the American Rheumatism Association, makes the study easily replicable in 






Curcuma longa extract reduces inflammatory and oxidative stress biomarkers in osteoarthritis of 





This double-blind randomized placebo-controlled clinical trials primary goal was to 
observe the effect of curcumin on clinical improvement in patients with knee osteoarthritis 
(KOA) as assessed by the Visual Analog Scale (VAS) and the Western Ontario and McMaster 
Universities Osteoarthritis index (WOMAC).  
 
Study Design:  
 
 The study was conducted at King George’s Medical University in Lucknow, India.  
Criteria for establishing a patient suffering from KOA were according to the guidelines proposed 
by The American College of Rheumatology. Further, participants were included if they were 
between the ages of 40-80.  Radiographic osteoarthritis of the knee was classified according to 
the Kellgren-Lawrence grading scale (see Table 2).  Participants were excluded if they were less 
than 40 years old or more than 80, if they suffered from rheumatoid arthritis, diabetes mellitus, 
renal insufficiency, hepatic disease, cardiovascular disease, gout, were pregnant, or with any 
other systemic disease. Inclusion and exclusion criteria is summarized in Table 7.   
 
 
Table 7. Patient Inclusion and Exclusion Criteria; Srivastave, S. et al 2016. 
 
Inclusion Criteria 










Other systemic diseases 
 
 Participants were assigned by computerized randomization to receive either 500 mg of 
curcumin and 50 mg/day of diclofenac or 500 mg placebo capsules along with 50 mg/day 
diclofenac.  The final sample size was 133 patients including 66 in the curcumin group and 67 in 
the placebo group.  Outcomes were measured on days 0, 60, and 120.  Measurements included 
the VAS, WOMAC, and biochemical markers including: Reactive Oxygen Species (ROS), 
serum IL-1Beta, and serum MDA.  The VAS is a subjective measurement, with use of a 
horizontal line which contains word descriptions at each end, ranging from 0-10 representing 
pain level.  Zero indicates no pain and 10 indicates unbearable pain. The patient marks one of the 
following options: no pain, mild pain, moderate pain, or severe pain. ROS and MDA are 
biomarkers of oxidative stress and serum IL-1Beta is a marker of inflammation.   
 Results were analyzed using the chi-square test to compare categorical variables, the 
unpaired t-test to compare discrete variables, and a paired t-test to compare mean change in 





 Outcomes focused on for this study included the VAS, WOMAC, and biochemical 
markers ROS, MDA, and IL-1Beta.  Eligible participant breakdown throughout the study is 










Table 8. Study participants; Srivastave, S. et al 2016. 
 
Participants Curcumin Placebo 
Initial 78 82 
Lost to follow-up after 60 
days 
7 8 
Lost to follow-up after 120 
days 
5 7 
Completed Study 66 67 
 
 Group comparison of the visual analog scale (VAS) showed statistical significance (P-
value <0.05) on Day 60 and Day 120 with scores being lower amongst the curcumin group.  The 
VAS score for curcumin at day 60 was 4.96 while the placebo group was 6.00.  At day 120 the 
VAS for the curcumin group was 4.03 and the placebo 5.11.  Further, statistical significance was 
seen amongst the WOMAC subcategories of pain and patient function between the two groups 
for follow-up day 60 and day 120.  In regards to pain, at day 60, the curcumin group was at 11.19 
and the placebo group 12.05.  At day 120, curcumin group was at 9.48 and the placebo group at 
10.16.  For patient function, at day 60 curcumin was 41.28 and placebo was 45.11, whereas, at 
day 120, curcumin was 32.14 and placebo at 33.88 (see table 9). 
 
 
Table 9. Effect of treatment on VAS and WOMAC scores between groups; Srivastave, S. et al 
2016.  
 
Parameters Curcumin Placebo P value 
VAS Score    
      Day 0 7.94 ± 0.13 7.66±0.14 0.15 
      Day 60 4.96±0.07 6.00±0.11 0.0001* 
      Day 120 4.03±0.08 5.11±0.14 0.0001* 
WOMAC Score    
Pain    
      Day 0 15.10±0.31 15.29±0.26 0.64 
      Day 60 11.19±0.26 12.05±0.21 0.01* 
      Day 120 9.48±0.17 10.16±0.16 0.06* 
Stiffness    
      Day 0 5.55±0.21 5.31±0.12 0.53 
      Day 60 4.51±0.21 4.70±0.23 0.54 
      Day 120 4.08±0.17 4.16±0.18 0.73 
Patient Function    
      Day 0 54.03±0.68 50.99±0.68 0.008 
      Day 60 41.28±0.51 45.11±0.37 0.0001* 





Biochemical outcomes, which is objective data, also showed statistical significance 
amongst groups for ROS at days 0. 60, and 120 respectively, and for MDA at day 60 and 120.  
The ROS for the curcumin group at day 0 was 3798 MFI compared to 2584 MFI for the placebo 
group.  For day 60, curcumin was 2553 MFI and the placebo 2144 MFI, and for day 120 the 
curcumin was 1200 MFI and the placebo group 2197 MFI.  For MDA at day 60 the curcumin 
group was 3.85 nmol/ml and the placebo 5.00 nmol/ml.  At day 120, the curcumin group MDA 
was 3.96 nmol/ml and the placebo group 4.91 nmol/ml (see Table 10). 
 
Table 10. Effect of treatment on biochemical parameters between the study groups; Srivastave, S. 
et al 2016.  
 
Parameters Curcumin Placebo P value 
IL-1b (pg/ml)    
      Day 0 126.4 ±19.94 131.5 ±19.79 0.85 
      Day 60 65.61 ±21.59 74.83 ±22.31 0.76 
      Day 120 21.11 ±1.176 35.82 ±7.53 0.55 
ROS (MFI)    
      Day 0 3798 ±1507.77 2584 ±671.74 0.001* 
      Day 60 2553 ±775.67 2144 ±1275.97 0.001* 
      Day 120 1200 ±864.08 2197 ±1378.90 0.0001* 
MDA (nmol/ml)    
      Day 0 5.02 ±0.16 5.15 ±0.14 0.57 
      Day 60  3.85 ±0.12 5.00 ±0.11 0.0001* 
      Day 120 3.69 ±0.12 4.91 ±0.11 0.0001* 
  
 Overall clinical assessment amongst participants showed statistically significant 
improvement in presence of joint crepitation, joint stiffness, and joint effusion between the two 
groups.  There was an overall reduction of 60% of participants with presence of joint crepitation 
for the curcumin group and 20% reduction for the placebo group.  A 64% overall reduction was 
seen in the curcumin group in regards to presence of joint stiffness and a 31.8% reduction for the 
placebo group.   Lastly, an overall reduction of 75.8% was seen in the curcumin group for joint 
effusion presence and 37% for the placebo group (see Table 11). 
 
Table 11. Clinical assessment parameters between the two groups; Srivastave, S. et al 2016.  
 
Parameters Curcumin Placebo group P value 
Reduction of joint 
crepitation 
60% 20% 0.001* 
Reduction of joint 
stiffness 
64% 31.8% 0.027* 
Reduction of joint 
effusion 





In conclusion this study showed that adjuvant therapy curcumin along with diclofenac 
produces overall significant improvement in patients with knee osteoarthritis.  Thus, it is 
proposed that patients with KOA should be given curcumin as soon as the diagnosis is made to 




One strength of this article is that it was performed as a double blind randomized control 
trial which helps eliminate some potential confounding variables.  Additionally, its use of 
objective data including measurements of reactive oxygen species (ROS), IL-1Beta, and MDA, 
which are biomarkers of inflammation and oxidative stress provide a more accurate account of 
efficacy. Objective data provides concrete evidence of improvements of knee osteoarthritis 
among the curcumin treatment group.  Another strength of the study is the use of multiple 
follow-up days, measuring all data at day 60 and then again at day 120.  This allows for 
continuous monitoring to see if improvements are shown throughout the four months and not just 
at the end of the study.   
 One of the drawbacks of this study was the small sample size.  In the end, only 133 
participants completed the study, 66 in the curcumin group and 67 in the placebo group.  This is 
not a very large number, and significance could have changed if the sample size was larger.  
Another drawback of the study was the fact that both groups used diclofenac, an NSAID used to 
treat knee osteoarthritis. Because of the combination of treatment, in the end, it remains 
unknown how much the curcumin really benefited the treatment group versus if the diclofenac 
was what benefited the group.   
Another consideration is if this study can be applied to the United States as it was 
performed in India.  However, osteoarthritis is a degenerative joint disease that can affect any 
person regardless of where they live in the country.  Further, the inclusion and exclusion criteria 
for this study were set according to the American College of Rheumatology, and due to this 







Curcuminoid Treatment for Knee Osteoarthritis: A Randomized Double-Blind Placebo-




This double-blinded randomized placebo-controlled study sought to determine the 
clinical efficacy of curcumin in reducing clinical symptoms of knee osteoarthritis as assessed by 
the McMaster Universities Osteoarthritis Index (WOMAC) score, Lequesne’s pain functional 
index (LPFI), and visual analogue score (VAS). The aim of this pilot study was to determine the 
efficacy of curcumin in alleviating OA symptoms when co-administered with the brand name 





The study included patients with a diagnosis of knee OA who were referred to the 
Baqiyatallah University Clinic in Tehran, Iran during 2011 and 2012. Participants were permitted 
to participate if they had primary knee OA with mild to moderate severity, as determined by 
radiological and clinical criteria. The radiological criteria is defined by the American College of 
Rheumatology, and the clinical criteria was determined by patients scoring on the VAS score. 
Participants had to score at least 40 mm on a 100 mm VAS score rating when assessed for the 
degree of pain on active movement. The study had several exclusion criteria which are listed in 
table 12.  
 
Table 12.  Patient Inclusion and Exclusion Criteria; Panahi Y. et al 2014. 
 
Inclusion Criteria 
Primary knee osteoarthritis with mild to moderate severity as defined by the American College 
of Rheumatology and the Visual Analogue Scale score of at least 40 mm on a 100 mm scale 
Bilateral OA 
Age less than 80 years old  
Exclusion Criteria 
Allergy to curcuminoids or other herbal medications  
Candidates for surgical joint replacement or any other surgical treatment 
OA secondary to trauma   
Rheumatoid arthritis  
Hemophilia  
Malabsorption disorders  
Active or generalized inflammatory disorders (erythrocyte sedimentation rate (ESR) greater 
than 20) 
Heart, renal or liver disease  
Corticosteroid use over 10 mg/day in the preceding 3 months  
History of psychological disorders  





Participants were randomly assigned using a 1:1 ratio scheme in consecutive order to 
receive either curcumin 1500 mg/day or placebo for 6 weeks. Patients in the curcumin group 
were instructed to take three 500 mg tablets each day. The curcumin capsules each contained 5 
mg Bioperine to enhance the absorption of the curcumin; the placebo tablets contained starch. 
During each week of the trial, regular consumption of the tablets was monitored. Both the 
curcumin group and the placebo group were allowed to take naproxen when they experienced 
intolerable discomfort. The final sample size that completed the trial included 19 participants in 
the curcumin group and 21 in the placebo group.  
Outcome measurements were assessed using the WOMAC, VAS and the LPFI. The 
WOMAC index was used to determine the severity of OA symptoms and included 5 items 
relating to pain, 2 items relating to stiffness, and 17 items to assess physical functioning. Each 
item is then rated on a scale of 0 to 4, with a total score of 0-20 for pain, 0-8 for stiffness, and 0-
68 for physical functioning.  
This study determined the severity of pain by using the VAS scores collected from 
participants. The VAS score ranges from a score of zero, indicating no pain at all, to a score of 
100 which signifies unbearable pain. The VAS scores are collected by having the patient mark 
on a horizontal line the number that correlates to his or her level of knee pain severity.  
The Lequesne’s pain functional index (LPFI) looks at pain, maximum distance walked, 
and activities of daily living (ADL). The pain and ADL scores range from 0 to 8 with zero 
representing no pain or no functional limitations and 8 representing maximum level of 
impairment. The maximum distance walked ranges from 0 to 6, with zero representing unlimited 
ability to walk and 6 signifying severe limitations with less than 100 meters of walking distance. 
Further, the LPFI score is increased by one point if the patient uses one crutch and two points if 
the patient uses two crutches. The LPFI scores range from 0 to 24, with higher scores 
representing a decreased health and more severe impairment.  
The statistical analysis was carried out by computers, and each parameter was assessed at 
baseline and at the end of the trial using a paired samples T-test. The differences in magnitude 
were assessed using independent t-tests. A p-value less than 0.05 was considered statistically 




Outcomes in this study focused on WOMAC scores, LPFI, and VAS scores among 
curcumin and placebo groups. The baseline characteristics between the two groups were matched 
for age, gender, BMI and mean WOMAC, LPFI, and VAS scores.  
Participants in the curcumin group had a statistically significant reduction in mean 
WOMAC scores with respect to global score, physical function, and stiffness at the end of the 
trial when compared to individuals in the placebo group. The WOMAC scores for individuals in 
the placebo group had no change in the score, pain, or physical function. However, participants 
in the placebo group had a statistically significant decrease in the stiffness subscale. When the 
two groups were compared, curcumin showed a decrease in WOMAC scores for measures of 
global assessment, pain, and physical functioning. However, no statistical significance was found 
between curcumin and placebo for a change in stiffness. Refer to table 14 for comparison among 
groups. 
When comparing LPFI and VAS scores among the two groups a statistically significant 
reduction in scores was seen in the curcumin group compared to the placebo. Additionally, 84% 
of subjects in the curcumin group reported a reduction in the use of naproxen compared to 
individuals in the placebo group (P value <0.001). However, reduction in the use of naproxen 
was based upon patients own recordings of usage. Patients receiving curcumin reported using 
250 to 500 mg of naproxen compared to individuals in the placebo group reporting use of 500 to 
750 mg of naproxen. 
Table 13 shows the breakdown of individuals among groups. The researchers determined 
that the loss of follow-up was not due to adverse effects associated with curcumin 
supplementation, with four patients in the placebo group reporting mild gastrointestinal 




Table 13. Study participants; Panahi, Y. 2014 
 
Participants Curcumin Placebo 
Initial 27 26 
Lost to follow-up  8 5 
Completed Study 19 21 
 
 
Table 14. Effect of treatment on WOMAC scores between groups; Panahi, Y. et al 2014.  
 





WOMAC Score     
Pain     
      Before 
treatment  
9.9± 4.1 10.5±4 <0.001* <0.001* 
      After 
treatment  
6.1±2.9  9.4±3.4 0.025* <0.001* 
Stiffness     
      Before 
treatment 
1.05±1.8 1.7±1.7 0.043* 0.912 
     After treatment  0.15±0.5 0.76±0.9 0.009* 0.912 
Patient function     
      Before 
Treatment  
31.8±14 32.4± 12.8 <0.001* <0.001* 
      After 
treatment  
18.7±10.3 30.4±9.4   
Global score     
     Before    
Treatment  
42.4±18.3 44.6±17.3 <0.001* 0.001* 
     After 
Treatment  





One of the strengths of this study was that it is a double-blinded randomized placebo-
controlled study.  Further, if participants did not complete the study or were noncompliant, they 
were not included in the overall results of the study. Another strength is the addition of Bioperine 
to the curcumin group which allowed for greater absorption of the compound and may have 
produced more efficacious results. The addition of Bioperine has been shown to increase blood 
concentrations of curcumin in the intestinal tissue and enhance permeability. In previous studies, 
curcumin has had limited efficacy due to its poor systemic absorption when taken by itself. 
Another strength of this study is that it is a randomized control trial which helps control 
confounding variables that otherwise could skew the results.  
The major limitation of this study was the small sample size. The study included a total 
of 40 patients that completed the trial which may make it difficult to generalize the findings to 
the larger population as a whole. Despite the small sample size, researchers were still able to 
demonstrate statistical significance for the effect of curcumin on improving WOMAC, VAS, and 
LPFI scores. A second limitation of this study was that participants were only supplemented with 
curcumin for a duration of 6 weeks. Considering that OA is a chronic condition, if patients 
benefited from use of curcumin, it is likely that he or she would supplement indefinitely. This 
makes it difficult to determine the long-term efficacy of curcumin from a trial lasting such a 
short duration. The third limitation of this study was that only patients with mild to moderate OA 
were allowed to participate. The trial does not address if patients suffering from severe OA are 
likely to benefit from curcumin supplementation.  
Another limitation is that the study did not clearly define what intolerable pain was, and 
therefore, it was up to each patient to determine if they needed naproxen. The study also relied 
on self -reported data of naproxen use. It is possible patients forgot to keep track of each time 
naproxen was used which could have significantly altered the results.  
Additionally, this study was performed in Iran and not the United States.  However, 
osteoarthritis is a degenerative joint disease that can be seen in any country.  Therefore, this 





To date, there is limited research on the effects of curcumin on symptom relief for 
osteoarthritis.  All three of the articles reviewed concluded that use of curcumin is as effective as 
other currently used treatments such as NSAIDs.  Additionally, curcumin has the added benefit 
of fewer gastrointestinal adverse effects. Side effects of curcumin supplementation include 
gastrointestinal upset such as diarrhea, flatulence, and abdominal bloating. Patients taking 
warfarin or other blood thinners should proceed with caution as long term use can thin the blood.  
An overview of the three studies including demographics, treatment, tests used, conclusion, and 
limitations can be seen in Table 15. 
The Kuptniratsaikul, V. et al 2014 study concluded that curcumin is an efficacious and 
safe alternative to the use of ibuprofen for the treatment of osteoarthritis.  Further, in regards to 
safety concerns, curcumin was been shown to have a better safety profile than ibuprofen in terms 
of abdominal pain and distension.  They found that curcumin can be provided at 2,000 mg/d for 
6 weeks or an even higher dose of up to 8,000 mg/d for 3 months without any serious adverse 
effects.  
The Srivastave, S. et al 2016 study concluded that adjuvant therapy of curcumin along 
with diclofenac produces significant improvement in patients with knee arthritis, and therefore, 
curcumin should be given as soon as the diagnosis is made.  Further, NSAIDs, if required, may 
be given for a short period, but curcumin may be prescribed for long durations without fear of 
gastrointestinal or kidney adverse effects. The Srivastave, S. et al study was the only study 
included in this review that used biochemical measures including ROS, serum IL-1Beta, and 
serum MDA.  This provided concrete results to support the effectiveness of curcumin. 
The Panahi, Y. et al 2014 study found curcumin to be effective in alleviating the 
symptoms and improving care of patients with osteoarthritis.  However, they concluded that 
these benefits should be exercised with caution due to limitations and further research needed.  
The Panahi, Y. et al study suggests that due to the positive results in this trial, future larger-scale 
trials should explore if curcumin can be used as a therapeutic regimen of patients suffering from 
knee osteoarthritis. 
Due to the lack of research on curcumin, all three research articles used in this review 
used different variables making comparisons difficult. The Kuptniratsaikul, V. et al study 
compared curcumin to ibuprofen. The Sirvastave, S. et al study compared curcumin and 
diclofenac versus placebo and diclofenac. The Panahi, Y. et al study compared curcumin with 
the addition of Bioperine to placebo. A limitation seen in all three studies was that they allowed 
the use of rescue drugs as needed for severe flare up of osteoarthritic symptoms. Due to this fact, 
it is difficult to assess whether the curcumin alone had positive effects in relieving OA symptoms 
versus if it was simply the use of NSAIDs or the combination of the two bringing about the 
effect. Another limitation of all three trials is the short duration of treatment with curcumin.  The 
longest duration of treatment amongst all three studies reviewed was only three months. This 
made it challenging to assess benefits of curcumin.  
Due to the limitations mentioned above, more research is needed on the use of curcumin 





Does curcumin supplementation when compared to NSAIDs, placebo, and rescue medications 
provide greater relief of arthritic symptoms in males and females between the ages of 40 and 80 
with a prior diagnosis of osteoarthritis? 
 
Based on the results of these small double-blinded trials, curcumin may be an effective 
alternative to NSAIDs in controlling pain associated with osteoarthritis symptoms with 
minimized gastrointestinal side effects. Therefore, curcumin may be a reasonable alternative to 
patient who cannot tolerate NSAIDs due to the GI and cardiovascular adverse effects. However, 
due to the lack of research to date, additional studies on the use of curcumin in the treatment of 
OA are needed before a definitive recommendation can be made to the general population for its 
usefulness in pain relief in patients with OA. Future studies should include larger population 
based studies with longer duration of supplementation to better assess the general population as a 
whole and the effectiveness of curcumin. Further, additional studies would provide more 
accurate results if the use of rescue medications was limited. However, it may be unrealistic and 









Table 15. Overview of Studies 
 
 Kuptniratsaikul, V.   et 
al 2014 
Srivastave, S. et al 
2016 
Panahi, Y. et al 2014 
Sample size 331 133 40 
Patient age At least 50 yo 40-80 yo Less than 80 yo 
Gender Males and Females Males and females Males and Females 
Location 8 tertiary hospitals in 
Thailand July 2010-
March 2012 
King George’s Medical 
University in Lucknow, 
India 
Baqiyatallah 
University Clinic in 
Tehran, Iraq 2011-2012 
Treatment Curcumin vs. Ibuprofen Curcumin and 
Diclofenac vs. Placebo 
and Diclofenac 
Curcumin vs. Placebo 
Study length 4 weeks 3 months 6 weeks 













Conclusion Curcumin is as effective 
as ibuprofen for the 
treatment of knee 
osteoarthritis with fewer 
gastrointestinal adverse 
effects in the curcumin 
group. 
 
Adjuvant therapy of 
curcumin along with 
diclofenac produces 
overall significant 
improvement in patients 
of knee OA.  
 
NSAIDs, if required, 
may be given for a short 
period but curcumin 
may be prescribed for 
long durations, without 
fear of damaging the GI 
or kidneys. 
Curcumin and the 
addition of Bioperine is 
an effective and safe 
alternative treatment 
for osteoarthritis. 
Limitations -Short duration 
-Rescue med Toradol 
used for exacerbations 
-Results mostly 
subjective in nature 
-Small sample size 
-Use of adjuvant 
diclofenac  
 
-Small sample size 
-Results were all 
subjective 
-Rescue med Naproxen 
used for exacerbations 
-Only treated mild to 
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